<DOC>
	<DOCNO>NCT01301612</DOCNO>
	<brief_summary>The primary study objective ass efficacy combination radiation therapy nimotuzumab cisplatin , compare combination radiation therapy plus cisplatin treatment Uterine Cervical Carcinoma ( UCC ) . The secondary study objective safety tolerability evaluation , determine treatment feasibility interim efficacy evaluation accord parameter routinely use oncology .</brief_summary>
	<brief_title>Study Nimotuzumab , Radiation Therapy Cisplatin Versus Radiation Therapy Cisplatin Treatment Stage IB e IVA UCC ( CORUS )</brief_title>
	<detailed_description>This phase II , randomize , control , open-label , multicenter , two-arm study . The study conduct Brazil purpose determine activity safety nimotuzumab term overall distant disease-free survival , radiological clinical gynecological examination , well biopsy , indicate , progression-free survival , local control long-term disease , frequency treatment-emergent adverse event , frequency severe treatment-emergent adverse event . All participate patient sign consent form undergo study-related procedure.The eligible patient stage IB IVA uterine cervical carcinoma randomize one two treatment group . Randomization treatment assignment perform company specifically contract purpose per research site disease stage ( IB2 IIIA versus IIIB IVA ) , 1:1 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Age &gt; 18 year ; Diagnosis histologically confirm stage IB2 ( &gt; 4 cm ) IVA pricklecell carcinoma adenocarcinoma uterine cervix adenosquamous carcinoma , accord FIGO system,7 ( see Appendix A guidance staging ) ; Measurable disease accord RECIST 1.139 least disease evaluable image method and/or gynecological examination ( magnetic resonance imaging ( MRI ) scan within six week prior randomization accept , compute tomography accept case MRI contraindicate ) ; Indication definitive treatment chemotherapy radiation therapy , investigator 's discretion ; Performance status &lt; 2 , accord Eastern Cooperative Oncology Group criteria 40 ( ECOG ; see Appendix C ) ; Adequate body function , indicate : Serum creatinine &lt; 1.2 mg/100 mL ; Creatinine clearance &gt; 60 mL/min ( estimate ) ; Bilirubin 1.5fold upper limit normal ( ULN ) transaminases , alkaline phosphatase gammaglutamyltransferase 2.5fold ULN ; Leucocytes &gt; 3,000/μL ; Neutrophils &gt; 1,500/μL ; Hemoglobin &gt; 10 g/dL ; Platelets &gt; 80,000/μL ; Signed informed consent form . Paraaortic lymph node involvement radiological and/or surgical staging , investigator 's discretion ; Current severe comorbidity , investigator 's opinion , would put patient significantly high risk jeopardize protocol compliance ; Current bowel inflammatory disease ; Current major neurological psychiatric disease , include clinically significant dementia seizure , investigator 's discretion ; Known hypersensitivity allergic reaction study treatment ; Current uncontrolled hypercalcemia ( &gt; 11,5 mg/dL , , grade &gt; 1 accord Common Terminology Criteria Adverse Events [ CTCAE ] v4.02 , US National Cancer Institute ) 41 ; Know HIV positive status ( enrollment patient hepatitis B C investigator 's discretion ) ; Pregnancy lactation ; Female patient , well partner , wish become pregnant unwilling use appropriate contraceptive method throughout study period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>carcinoma adenocarcinoma uterine cervix adenosquamous carcinoma</keyword>
</DOC>